Related Experiment Video
Updated: Jan 20, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
EGFR Mutation Analysis in Non-small Cell Lung Carcinoma from Tissue Samples Using the Fully Automated Idylla™ qPCR
Simon Heeke1,2, Paul Hofman3,4,5
1Institute of Research on Cancer and Ageing of Nice (IRCAN), Inserm U1081, CNRS UMR7284, Université Côte d'Azur, Nice, France.
Abstract:
The introduction of tyrosine-kinase inhibitors (TKI) targeting specific EGFR mutations for the treatment non-small cell lung cancer patients (NSCLC) dramatically increased the clinical outcome in a subset of patients harboring specific activating EGFR mutations. Three different generations of TKI have been developed until now, demonstrating increasing progression-free survival as well as overall survival. However, to benefit of the treatment, the analysis of the genomic content of each patient is mandatory. Additionally, resistance mutations are prevalent and occur frequently and rapidly during treatment. Therefore, tests to detect EGFR mutations at initial diagnosis as well as during treatment, e.g., from liquid biopsies, have been developed and implemented in clinical daily practice for theranostic purpose.As EGFR mutation testing has to be highly reliable, fast, and easy to perform, the automatic qPCR system Idylla™ has been developed and implemented for clinical mutation testing from tissue samples and soon from circulating free DNA. Therefore, we here describe how the Idylla™ system can be used for the analysis of EGFR mutations in NSCLC patients. Importantly, as the results are massively influenced by the preanalytical steps, we also provide information on the correct sample selection to avoid nonconclusive results.
Insights
EGFR mutation testing is crucial for non-small cell lung cancer (NSCLC) patients treated with tyrosine-kinase inhibitors (TKI). The Idylla™ system offers a reliable method for EGFR mutation analysis, improving theranostic approaches.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genomics
Background:
- Tyrosine-kinase inhibitors (TKI) targeting EGFR mutations have improved outcomes for non-small cell lung cancer (NSCLC) patients.
- Resistance mutations frequently emerge during TKI treatment, necessitating continuous monitoring.
- Genomic analysis is mandatory for effective TKI therapy and theranostic applications.
Purpose of the Study:
- To describe the utility of the Idylla™ system for EGFR mutation analysis in NSCLC.
- To highlight the importance of preanalytical steps for accurate mutation detection.
- To provide guidance on sample selection for reliable EGFR mutation testing.
Main Methods:
- Utilized the automated Idylla™ quantitative PCR (qPCR) system for EGFR mutation analysis.
- Focused on EGFR mutation testing from tissue samples.
- Discussed the impact of preanalytical variables on test results.
Main Results:
- The Idylla™ system provides a reliable, fast, and user-friendly platform for EGFR mutation testing.
- Proper sample selection and preanalytical handling are critical for obtaining conclusive results.
- The system is suitable for clinical daily practice in theranostic settings.
Conclusions:
- The Idylla™ system is a valuable tool for EGFR mutation analysis in NSCLC patients.
- Optimized preanalytical procedures are essential for maximizing the diagnostic accuracy of EGFR testing.
- This approach supports personalized medicine strategies in NSCLC treatment.
Related Concept Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
07:39The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
07:53Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
04:453-Dimensional Culture of Lung Carcinoma Cells: A Method To Study Cell-Matrix Interactions
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure